High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. - Wikidata - wikimedia - TriplyDB

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

http://www.wikidata.org/entity/Q33736193

about

Natalizumab in Multiple Sclerosis: Long-Term Management.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.

P2860

Q33754882-C84783ED-2541-4E5F-A596-EB2398CA71AE Q42361890-8E044EDB-C8B9-49BB-A5E2-C151130B7234 Q45066717-1BDD92FA-FABD-4896-9609-C6A82A2E1F41

P2860

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

http://www.wikidata.org/entity/Q33736193

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

@ast

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

@en

type

label

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

@ast

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

@en

prefLabel

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

@ast

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

@en

P1433

Q33736193-0DF5A2A9-EDF3-447B-A447-FDC85F1D2566

P1476

Q33736193-EC8819AB-F20F-479C-B276-4C9C51495D30

P2093

Q33736193-2F32627C-B0CA-4E72-B816-BC2F12DB011D

Q33736193-6C066D38-4BDE-445D-9DA8-CDED1C531629

Q33736193-8BC0511D-0535-409B-8329-957005433543

Q33736193-939BE775-E780-488E-8DF8-CED5A31C0566

Q33736193-9F07C9B4-85F0-4246-9852-105887748C3C

Q33736193-A31F9EF5-0AA9-4B00-A262-D028A8EB2B3C

Q33736193-A575EC36-AD38-4585-88F9-C7D3B431D7D3

P2860

Q33736193-0839DDB6-763A-410C-8C3F-591C27F9D99A

Q33736193-0D36E95F-43ED-4C06-BD75-14540A969E5F

Q33736193-1796CF5D-635A-4F0C-8583-C649B980B72E

Q33736193-1BE60942-BCD7-4EA9-96C5-6BE69DA9CB4D

Q33736193-211BBCCE-AC6E-4FE7-B160-2565A396F9C9

Q33736193-300C5335-C9F7-4424-8E47-222B6ED895C4

Q33736193-46332E81-7446-42E8-A1D7-8F89649DEF01

Q33736193-62FC57D2-4725-4B1C-8084-F94D8EADB44F

Q33736193-64BB0FB0-5EC7-4359-BFAC-6B253F4EC33D

Q33736193-6975CEB4-7028-41BD-9A35-AF39216FC1C1

P2888

Q33736193-4602102D-20E4-4A2F-980A-770461894704

P304

Q33736193-024CE3FD-22E4-4472-BA53-F44A2862BBE7

P31

Q33736193-0d99e066-ecf4-4fb5-88e6-3b8131c2ce04

Q33736193-A7985AEC-7012-4690-8612-30E8DDF1A493

P356

Q33736193-9E99D752-2513-4CB6-A2A3-CF313A2CA9F6

P433

Q33736193-E4A62399-C3C9-4E34-BB49-E22F45DB7180

P478

Q33736193-21D9A364-EA9F-40BB-96E6-06773DD1687B

P50

Q33736193-18645F9F-1CAA-4373-9A35-29C3B727B85F

P577

Q33736193-292B085F-FEF9-4094-9B8D-8284179E1B62

P6179

Q33736193-0C56B593-81CC-48AB-B85F-09EB0D31F4D1

P698

Q33736193-26D6DA51-FDD0-45FD-8C32-5B64F1130C6F

P932

Q33736193-F3659867-9021-4A36-8183-DBA5085FB5AB

P356

S40120-016-0058-0

P1433

Neurology and therapy

P1476

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

@en

P2093

Alessia di Sapio

http://www.w3.org/2001/XMLSchema#string

Francesca Sperli

http://www.w3.org/2001/XMLSchema#string

Manuela Matta

http://www.w3.org/2001/XMLSchema#string

Marco Capobianco

http://www.w3.org/2001/XMLSchema#string

Maria Malentacchi

http://www.w3.org/2001/XMLSchema#string

Marianna Lo Re

http://www.w3.org/2001/XMLSchema#string

Simona Malucchi

http://www.w3.org/2001/XMLSchema#string

P2860

Optimizing treatment success in multiple sclerosis

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

P2888

s40120-016-0058-0

P304

145-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40120-016-0058-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Bertolotto

P577

2016-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039029923

http://www.w3.org/2001/XMLSchema#string

P698

27915429

http://www.w3.org/2001/XMLSchema#string

P932

5447551

http://www.w3.org/2001/XMLSchema#string